Connor Clark & Lunn Investment Management Ltd. Has $716,000 Stake in Becton, Dickinson and Company (NYSE:BDX)

Connor Clark & Lunn Investment Management Ltd. reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 48.6% during the third quarter, HoldingsChannel reports. The firm owned 2,970 shares of the medical instruments supplier’s stock after selling 2,803 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Becton, Dickinson and Company were worth $716,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Tidal Investments LLC increased its holdings in shares of Becton, Dickinson and Company by 47.6% during the first quarter. Tidal Investments LLC now owns 13,313 shares of the medical instruments supplier’s stock worth $3,294,000 after buying an additional 4,293 shares in the last quarter. iA Global Asset Management Inc. acquired a new position in Becton, Dickinson and Company in the 1st quarter worth about $399,000. Swedbank AB bought a new position in Becton, Dickinson and Company in the first quarter valued at about $35,799,000. Atria Investments Inc boosted its stake in shares of Becton, Dickinson and Company by 11.8% during the first quarter. Atria Investments Inc now owns 18,370 shares of the medical instruments supplier’s stock valued at $4,546,000 after purchasing an additional 1,937 shares in the last quarter. Finally, Cetera Investment Advisers boosted its stake in shares of Becton, Dickinson and Company by 380.8% during the first quarter. Cetera Investment Advisers now owns 58,923 shares of the medical instruments supplier’s stock valued at $14,580,000 after purchasing an additional 46,668 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $221.98 on Friday. The stock has a market capitalization of $64.16 billion, a price-to-earnings ratio of 37.37, a PEG ratio of 1.68 and a beta of 0.43. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $249.89. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. The stock’s 50 day moving average price is $234.39 and its two-hundred day moving average price is $234.23.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the company posted $3.42 earnings per share. The business’s quarterly revenue was up 6.9% on a year-over-year basis. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be paid a $1.04 dividend. The ex-dividend date is Monday, December 9th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a dividend yield of 1.87%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 63.97%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on BDX shares. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Evercore ISI upped their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, Raymond James lowered their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $283.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.